NasdaqGS:INCYBiotechs
Incyte (INCY) Wins European Approval For Opzelura In Adult Atopic Dermatitis
Incyte received European Commission approval for Opzelura (ruxolitinib) cream to treat moderate atopic dermatitis in adults.
This is Opzelura's second indication in Europe following its earlier approval for non segmental vitiligo.
The decision expands Incyte's dermatology footprint in Europe and adds a new potential use case for Opzelura.
For investors tracking Incyte, ticker NasdaqGS:INCY, the European approval for Opzelura comes as the stock trades at $127.1. The company has posted...